Artikel
Establishment of an in vivo model to examine the osteoanabolic epigenome
Suche in Medline nach
Autoren
-
Hiroaki Saito
- Heisenberg-Group for Molecular Skeletal Biology , Department of Trauma, Hand & Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
-
Zeynab Najafova
- Clinic for General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany
-
Katharina Jähn
- Heisenberg-Group for Molecular Skeletal Biology , Department of Trauma, Hand & Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
-
Hanna Taipaleenmäki
- Heisenberg-Group for Molecular Skeletal Biology , Department of Trauma, Hand & Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
-
Andreas Gasser
- Heisenberg-Group for Molecular Skeletal Biology , Department of Trauma, Hand & Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
-
Steven A. Johnsen
- Clinic for General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany
-
Eric Hesse
- Heisenberg-Group for Molecular Skeletal Biology , Department of Trauma, Hand & Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| Veröffentlicht: | 10. Oktober 2016 |
|---|
Gliederung
Text
Objectives: Increasing bone formation is an effective approach to prevent osteoporotic fractures. Although the intermittent administration of PTH is an established osteoanabolic therapy and an anti-Sclerostin antibody (Scle-AB) is currently being tested in phase 3 clinical trials, a great need exists for additional bone anabolic agents. Thus, in the context of a bi-national consortium we aim to uncover novel epigenomic networks controlling bone formation to identify new epigenomic approaches to osteoanabolic therapy.
Methods: We generated tamoxifen-inducible, osteoblast-specific reporter mice (Osx1-Cre-ERT2;dtTomato) to isolate genetically-labeled osteoblasts directly from bones by fluorescent activated cell sorting (FACS). After tamoxifen injection, adult mice were treated with Scle-AB or vehicle and osteoblasts were enriched from long bones by FACS after collagenase digestion. Of all collected cells, approximately 3% were tomato-positive. Purified osteoblasts were then subjected to epigenome analyses. Therefore, chromatin was isolated followed by an analysis of a set of post-translational histone modifications, including markers of active (H3K4me1, H3K4me3, H3K27ac) and repressed (H3K27me3) genes.
Results and Conclusion: Our preliminary results obtained by chromatin immunoprecipitation (ChIP) showed the presence of H3K4me1 on the enhancer of Collagen 1, as well as the constitutively expressed Beta-actin (Actb) gene, but not on the inactive even-skipped homeobox 1 (Evx1) gene. While these analyses confirm the functionality of the experimental system, the ongoing genome-wide massively parallel high throughput sequencing following ChIP (ChIP-Seq) are expected to reveal novel molecular mechanisms regulating bone formation.
We have established an in vivo model allowing the investigation of the osteoanabolic epigenomic landscape, which might provide a basis for the development of novel bone anabolic anti-osteoporosis therapies.
